Table 1 |
||||
|
Baseline characteristics in RA patients who were receiving MTX and comparison between patients with and without abnormal liver stiffness measurement (LSM) |
||||
|
All patients (n = 105) |
LSM < 5.3 kPa(n = 81) |
LSM > 5.3 kPa(n = 24) |
P-value |
|
|
|
||||
|
Demographic variables |
||||
|
Age, years |
54.0 (25, 73) |
52.5 ± 10.3 |
52.3 ± 11.8 |
0.852 |
|
Male gender |
20 (19.0) |
16 (19.8) |
4 (16.7) |
0.736 |
|
Body mass index, kg/m2 |
22.1 (18.1, 27.6) |
22.1 ± 2.5 |
22.3 ± 2.4 |
0.723 |
|
Metabolic syndrome, number patients (%) |
6 (5.7) |
3 (3.7) |
3 (12.5) |
0.105 |
|
Disease duration, weeks |
140.4 (26.1, 739.2) |
171.8 ± 123.9 |
240.5 ± 159 |
0.059 |
|
Laboratory variables |
||||
|
C-reactive protein, mg/L |
1.2 (0, 124.0) |
3.1 ± 5.7 |
6.9 ± 25.1 |
0.766 |
|
Erythrocyte sedimentation rate, mm/hr |
33.0 (2, 111) |
37.3 ± 22.3 |
32.4 ± 20.7 |
0.362 |
|
White blood cells, count/mm3 |
5,960.0 (2,390.0, 12,870.0) |
6,355.9 ± 2,009.0 |
5,801.7 ± 1,853.9 |
0.319 |
|
Hemoglobin, g/dL |
12.7 (9.9, 16.2) |
12.7 ± 1.1 |
13.0 ± 1.0 |
0.324 |
|
Platelet count, × 1,000/mm3 |
241.0 (134.0, 470.0) |
253.0 ± 60.3 |
250.8 ± 69.0 |
0.723 |
|
Prothrombin time, INR |
0.9 (0.8, 1.2) |
1.0 ± 0.1 |
1.0 ± 0.1 |
0.726 |
|
Glucose, mg/dL |
85.0 (70.0, 125.0) |
87.4 ± 10.7 |
86.4 ± 5.0 |
0.652 |
|
Blood urea nitrogen, mg/dL |
14.4 (0.9, 28.1) |
15.2 ± 4.8 |
14.1 ± 4.6 |
0.249 |
|
Creatinine mg/dL |
0.7 (0.5, 1.3) |
0.7 ± 0.2 |
0.7 ± 0.1 |
0.858 |
|
Uric acid, mg/dL |
3.8 (1.5, 8.9) |
4.0 ± 1.2 |
4.1 ± 1.8 |
0.582 |
|
Aspartate aminotransferase, IU/L |
21.0 (13.0, 34.0) |
21.9 ± 5.5 |
22.4 ± 6.8 |
0.881 |
|
Alanine aminotransferase, IU/L |
17.0 (8.0, 39.0) |
18.9 ± 7.7 |
19.0 ± 7.7 |
0.879 |
|
Total protein, mg/dL |
6.9 (5.5, 7.9) |
7.0 ± 0.4 |
7.0 ± 0.5 |
0.730 |
|
Serum albumin, mg/dL |
4.3 (3.5, 4.9) |
4.3 ± 0.3 |
4.2 ± 0.4 |
0.815 |
|
Total bilirubin, mg/dL |
0.6 (0.2, 1.1) |
0.6 ± 0.2 |
0.6 ± 0.2 |
0.461 |
|
Alkaline phosphatase, IU/L |
52.0 (38.0, 110.0) |
56.4 ± 17.0 |
54.7 ± 13.1 |
0.976 |
|
Gamma-glutamyltranspeptidase, IU/L |
17.0 (5.0, 53.0) |
22.6 ± 15.1 |
26.3 ± 19.1 |
0.340 |
|
Triglyceride, mg/dL |
90.0 (26.0, 269.0) |
108.9 ± 55.4 |
92.2 ± 41.4 |
0.197 |
|
High density cholesterol, mg/dL |
55.0 (19.0, 86.0) |
55.9 ± 10.4 |
53.2 ± 19.1 |
0.772 |
|
Low density cholesterol, mg/dL |
105.4 (52.8, 172.6) |
108.8 ± 26.8 |
107.4 ± 26.8 |
0.743 |
|
Cumulative dose of medication, mg |
||||
|
Methotrexate (105 patients) |
2,032.5 (285.0, 7,800.0) |
2,334.0 ± 1,939.9 |
3,127.9 ± 2,072.7 |
0.086 |
|
Leflunomide (53 patients) |
7,800.0 (280.0, 38,520.0) |
9,291.1 ± 9,331.8 |
19,919.3 ± 12,716.8 |
0.008 |
|
Sulfasalazine (82 patients) |
360,000.0 (30,000.0, 6,028,000.0) |
727,778.7 ± 969,150.7 |
1,093,547.6 ± 1,330,930.2 |
0.111 |
|
Hydroxychloroquine (65 patients) |
94,600.0 (4,200.0, 868,000.0) |
115,248.0 ± 120,975.1 |
182,013.3 ± 208,807.9 |
0.129 |
|
Prednisolone (89 patients) |
3,015.0 (372.5, 20,212.5) |
4,642.1.0 ± 4,196.7 |
6,756.7.1 ± 6,156.5 |
0.472 |
|
Meloxicam (90 patients) |
6,273.8 (210.0, 2,895,000.0) |
90,205.0 ± 363,930.2 |
161,274.6 ± 644,791.4 |
0.793 |
|
Celecoxib (70 patients) |
163,000.0 (1,000.0, 1,503,000.0) |
218,505.7 ± 253,487.6 |
316,705.9 ± 313,982.7 |
0.239 |
|
LSM |
||||
|
LSM, kPa, median (range) |
4.4 (2.8, 17.8) |
NA |
NA |
NA |
|
LSM, kPa, median (IQR) |
0.14 (0.02, 0.29) |
NA |
NA |
NA |
|
Success rate, %, median (IQR) |
100.0 (63.0, 100.0) |
NA |
NA |
NA |
|
|
||||
|
Values are expressed as median (range, IQR), number (%), or mean ± SD. INR, international normalized ratio; NA: not applicable. |
||||
|
Lee et al. Arthritis Research & Therapy 2012 14:R232 doi:10.1186/ar4075 |
||||
